Likewise, adapting PA and LF components to increase their biological activity and minimize toxicity, synthesizing mutant PA moieties with more potent antiangiogenic and tumor growth properties [43], and developing anti-ANTXR1 antibodies have also been explored. The gene discussed is ANTXR1; the disease is neoplasm.